| Schedule of Basic and Diluted Net Income Per Share Attributable to Common Stockholders |
The
following table sets forth the computation of the Company’s basic and diluted net income per share attributable to common stockholders
for the thirteen week periods ended March 29, 2026 and March 30, 2025 (in thousands, except share and per share amounts):
| |
|
Thirteen Weeks Ended |
|
| |
|
March 29, |
|
|
March 30, |
|
| |
|
2026 |
|
|
2025 |
|
| Numerator for basic income per share: |
|
|
|
|
|
|
|
|
| Net income - basic |
|
$ |
5,250 |
|
|
$ |
4,812 |
|
| Numerator for diluted income per share |
|
|
|
|
|
|
|
|
| Senior unsecured convertible notes |
|
|
(4,882 |
) |
|
|
— |
|
| July 2024 Notes derivative liability and interest expense, net of tax |
|
|
— |
|
|
|
(3,138 |
) |
| Third SAFE |
|
|
(49 |
) |
|
|
20 |
|
| Net income - diluted |
|
$ |
319 |
|
|
$ |
1,694 |
|
| Denominator: |
|
|
|
|
|
|
|
|
| Weighted average shares: |
|
|
|
|
|
|
|
|
| Denominator for basic income per share |
|
|
124,279,055 |
|
|
|
80,209,585 |
|
| Effect of dilutive securities: |
|
|
|
|
|
|
|
|
| Senior unsecured convertible notes |
|
|
16,912,704 |
|
|
|
|
|
| July 2024 Notes derivative liability |
|
|
— |
|
|
|
27,364,717 |
|
| Third SAFE |
|
|
2,750,000 |
|
|
|
2,750,000 |
|
| Stock options and RSUs |
|
|
14,705,403 |
|
|
|
1,489,794 |
|
| Warrants |
|
|
166,460 |
|
|
|
487,794 |
|
| Deferred consideration |
|
|
4,973,840 |
|
|
|
— |
|
| Denominator for diluted income per share |
|
|
163,787,462 |
|
|
|
112,302,063 |
|
| Net income per share: |
|
|
|
|
|
|
|
|
| Net income - basic |
|
$ |
0.04 |
|
|
$ |
0.06 |
|
| |
|
|
|
|
|
|
|
|
| Net income– diluted |
|
$ |
0.00 |
|
|
$ |
0.02 |
|
|
The
following table sets forth the computation of the Company’s basic and diluted net loss per share attributable to common stockholders
(in thousands, except share and per share amounts):
| |
|
Fiscal Year Ended |
|
| |
|
December 28, |
|
|
December 29, |
|
| |
|
2025 |
|
|
2024 |
|
| Numerator for basic loss per share: |
|
|
|
|
|
|
| Net loss from continuing operations |
|
$ |
(44,254 |
) |
|
$ |
(54,444 |
) |
| Net loss from discontinued operations |
|
|
(1,100 |
) |
|
|
(2,007 |
) |
| Net loss |
|
|
(45,354 |
) |
|
|
(56,451 |
) |
| Numerator for diluted loss per share |
|
|
|
|
|
|
|
|
| Impact of September 2024 Notes derivative liability and interest expense,
net of tax |
|
|
— |
|
|
|
(35,886 |
) |
| Net loss |
|
$ |
(45,354 |
) |
|
$ |
(92,337 |
) |
| Denominator: |
|
|
|
|
|
|
|
|
| Weighted average shares: |
|
|
|
|
|
|
|
|
| Denominator for basic loss per share |
|
|
87,108,928 |
|
|
|
66,655,837 |
|
| Effect of dilutive securities: |
|
|
|
|
|
|
|
|
| September 2024 Notes derivative liability |
|
|
— |
|
|
|
9,137,711 |
|
| Denominator for diluted loss per share |
|
|
87,108,928 |
|
|
|
75,793,548 |
|
| Net loss per share: |
|
|
|
|
|
|
|
|
| Basic: |
|
|
|
|
|
|
|
|
| Continuing operations |
|
$ |
(0.51 |
) |
|
$ |
(0.82 |
) |
| Discontinued operations |
|
|
(0.01 |
) |
|
|
(0.03 |
) |
| Net loss |
|
$ |
(0.52 |
) |
|
$ |
(0.85 |
) |
| Diluted |
|
|
|
|
|
|
|
|
| Continuing operations |
|
$ |
(0.51 |
) |
|
$ |
(1.19 |
) |
| Discontinued operations |
|
|
(0.01 |
) |
|
|
(0.03 |
) |
| Net loss |
|
$ |
(0.52 |
) |
|
$ |
(1.22 |
) |
|
| Schedule of Potential Common Shares Excluded from Computation of Diluted Net Loss Per Share of Common Stock |
The
following table presents the potential common shares outstanding that were excluded from the computation of diluted net loss per share
of common stock as of the periods presented because including them would have been anti-dilutive:
| |
|
Thirteen Weeks Ended |
|
| |
|
March 29,
2026 |
|
|
March 30,
2025 |
|
| Convertible notes |
|
|
65,722,738 |
|
|
|
37,333,318 |
|
| Total potential common shares excluded from diluted
net loss per share |
|
|
65,722,738 |
|
|
|
37,333,318 |
|
|
The
following table presents the potential common shares outstanding that were excluded from the computation of diluted net loss per share
of common stock as of the periods presented because including them would have been anti-dilutive:
| |
|
Fiscal Year Ended |
|
| |
|
December 28, |
|
|
December 29, |
|
| |
|
2025 |
|
|
2024 |
|
| Common stock warrants |
|
|
218,847 |
|
|
|
25,434,069 |
|
| Convertible notes |
|
|
82,460,428 |
|
|
|
27,364,717 |
|
| Stock options and RSUs issued and outstanding |
|
|
8,084,064 |
|
|
|
11,979,368 |
|
| Third SAFE Agreement |
|
|
2,750,000 |
|
|
|
— |
|
| Deferred consideration shares |
|
|
11,640,506 |
|
|
|
— |
|
| Potential common shares excluded from diluted net
loss per share |
|
|
105,153,845 |
|
|
|
64,778,154 |
|
|